Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA To Sponsors: Tell Us More About Your Drug Development Before We Meet

Executive Summary

Requests for meetings with FDA staff about products in development should include pertinent details about pediatric study plans, human factors engineering plans and combination product information; new guidance documents on formal meetings under PDUFA VI and communications with IND sponsors operationalize user fee program commitments and will promote earlier, more thorough engagement, agency says.


Related Content

US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products
Patient Experience Data: Industry Seeks US FDA Clarity On Submission Pathway And Labeling
FDA Reviewers Share CMC, GMP Challenges In Last Year's Rush To Approve New Therapies
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
IND Sponsors Should Not Contact FDA Reviewers Directly, Draft Guidance Asserts
REMS, ‘Breakthrough’ Meetings Get ‘Type B’ Tag In Revised FDA Guidance





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts